These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 25688137)

  • 1. Gene of the month: PIK3CA.
    Lai K; Killingsworth MC; Lee CS
    J Clin Pathol; 2015 Apr; 68(4):253-7. PubMed ID: 25688137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [PI3K inhibitor].
    Yano S; Takeuchi S; Yamada T; Mouri H; Yamashita K; Ohtsubo K; Yasumoto K
    Gan To Kagaku Ryoho; 2011 Jan; 38(1):23-6. PubMed ID: 21368457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
    Polivka J; Janku F
    Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.
    Tanizaki J; Okamoto I; Fumita S; Okamoto W; Nishio K; Nakagawa K
    Oncogene; 2011 Sep; 30(39):4097-106. PubMed ID: 21499301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic deregulation of the PIK3CA oncogene in oral cancer.
    Murugan AK; Munirajan AK; Tsuchida N
    Cancer Lett; 2013 Sep; 338(2):193-203. PubMed ID: 23597702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Approaches and limitations of phosphatidylinositol-3-kinase pathway activation status as a predictive biomarker in the clinical development of targeted therapy.
    Coughlin CM; Johnston DS; Strahs A; Burczynski ME; Bacus S; Hill J; Feingold JM; Zacharchuk C; Berkenblit A
    Breast Cancer Res Treat; 2010 Nov; 124(1):1-11. PubMed ID: 20803067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.
    Li H; Jin X; Zhang Z; Xing Y; Kong X
    Cell Biochem Funct; 2013 Jul; 31(5):427-33. PubMed ID: 23086777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting PI3K signaling as a therapeutic approach for colorectal cancer.
    Zhang J; Roberts TM; Shivdasani RA
    Gastroenterology; 2011 Jul; 141(1):50-61. PubMed ID: 21723986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PIK3CA mutation is associated with a favorable prognosis among patients with curatively resected esophageal squamous cell carcinoma.
    Shigaki H; Baba Y; Watanabe M; Murata A; Ishimoto T; Iwatsuki M; Iwagami S; Nosho K; Baba H
    Clin Cancer Res; 2013 May; 19(9):2451-9. PubMed ID: 23532889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting AKT/PKB to improve treatment outcomes for solid tumors.
    Iida M; Harari PM; Wheeler DL; Toulany M
    Mutat Res; 2020; 819-820():111690. PubMed ID: 32120136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer-specific mutations in PIK3CA are oncogenic in vivo.
    Bader AG; Kang S; Vogt PK
    Proc Natl Acad Sci U S A; 2006 Jan; 103(5):1475-9. PubMed ID: 16432179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Targeting Ras-PI3K/mTOR pathway and the predictive biomarkers in endometrial cancer].
    Oda K
    Gan To Kagaku Ryoho; 2011 Jul; 38(7):1084-7. PubMed ID: 21772091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of the PI3K pathway in colorectal cancer.
    Papadatos-Pastos D; Rabbie R; Ross P; Sarker D
    Crit Rev Oncol Hematol; 2015 Apr; 94(1):18-30. PubMed ID: 25591826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
    Beck JT; Ismail A; Tolomeo C
    Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PI3K inhibitors for cancer therapy: what has been achieved so far?
    Wu P; Liu T; Hu Y
    Curr Med Chem; 2009; 16(8):916-30. PubMed ID: 19275602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches.
    Ligresti G; Militello L; Steelman LS; Cavallaro A; Basile F; Nicoletti F; Stivala F; McCubrey JA; Libra M
    Cell Cycle; 2009 May; 8(9):1352-8. PubMed ID: 19305151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Colon carcinoma cells harboring PIK3CA mutations display resistance to growth factor deprivation induced apoptosis.
    Wang J; Kuropatwinski K; Hauser J; Rossi MR; Zhou Y; Conway A; Kan JL; Gibson NW; Willson JK; Cowell JK; Brattain MG
    Mol Cancer Ther; 2007 Mar; 6(3):1143-50. PubMed ID: 17363507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncogenic PI3K and its role in cancer.
    Samuels Y; Ericson K
    Curr Opin Oncol; 2006 Jan; 18(1):77-82. PubMed ID: 16357568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mouse Models for Exploring the Biological Consequences and Clinical Significance of
    Mitchell CB; Phillips WA
    Biomolecules; 2019 Apr; 9(4):. PubMed ID: 31018529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.